Earlier this year, several
AZA-accredited zoological facilities in Washington state received an
unannounced inspection by the FDA. While not directly stated, the visits
were focused on BSE and those veterinary, animal care, and animal nutrition
aspects that could be related to federal efforts to detect and control
this disease. The inspector provided educational materials and
a brief overview of BSE to selected staff that met with him.
Food storage, supplier information,
feed transport, and feed record keeping was closely examined.
Zoos were requested to maintain manufacturer labels for one year and
track which feed was provided to which zoo ruminants. Storage
facilities were examined for proximity of feeds containing animal protein
to other feeds. Overall, the focus appeared to be the ability
to track a food substance from the supplier to the animals that ingested
Drugs and other therapeutics
administered to animals were also inspected, with close attention paid
to nutraceuticals and appropriate FDA labeling/licensing (e.g., products
labeled for humans prescribed to animals). One concern identified
with the practice of prescribing bovine-origin chondroitin-glucosamine
joint supplements to zoo ruminants (e.g., Cosequin). Per FDA regulations,
bovine origin products cannot be administered to ruminants.
Final inspection reports were
not provided to the facilities. Facilities were instructed to
contact their regional FDA office to obtain a copy of the report.
Further action or follow-up by the FDA has not occurred at any of the
other facilities at the time of this announcement.
2008 Update on Feed Enforcement Activities to Limit the Spread of BSE;
FDA issues regulation on animal
feeds with added safeguards against BSE; http://www.fda.gov/cvm/CVM_Updates/UpdateBSErevised.htm